FDA Seeks Feedback on Biosimilar Fee Forms for Faster Meds
Published Date: 2/3/2025
Notice
Summary
The FDA is asking for approval to collect info about the Biosimilars User Fee Program, which helps speed up the review of new biosimilar medicines. This affects drug companies who pay fees to get their products reviewed faster. The review process is moving forward, so expect some updates on timing and fees soon!
No Economic Impacts Identified for this Document
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in